Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs

被引:81
作者
Sadowski, Ivan [1 ]
Hashemi, Farhad B. [2 ]
机构
[1] Univ British Columbia, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada
[2] Univ Tehran Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
关键词
AIDS; HIV; Cure; Anti-retroviral therapy; Virus latency; Latency-reversing agents; Shock and kill; Transcriptional regulation; Lock and block; Genome editing; Immune modulation; HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; ANTIRETROVIRAL THERAPY; INTEGRATED HIV-1; GENE-EXPRESSION; REVERSAL AGENTS; VIRAL LATENCY; SMAC MIMETICS; EX-VIVO; CURE;
D O I
10.1007/s00018-019-03156-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
35 years since identification of HIV as the causative agent of AIDS, and 35 million deaths associated with this disease, significant effort is now directed towards the development of potential cures. Current anti-retroviral (ART) therapies for HIV/AIDS can suppress virus replication to undetectable levels, and infected individuals can live symptom free so long as treatment is maintained. However, removal of therapy allows rapid re-emergence of virus from a highly stable reservoir of latently infected cells that exist as a barrier to elimination of the infection with current ART. Prospects of a cure for HIV infection are significantly encouraged by two serendipitous cases where individuals have entered remission following stem cell transplantation from compatible HIV-resistant donors. However, development of a routine cure that could become available to millions of infected individuals will require a means of specifically purging cells harboring latent HIV, preventing replication of latent provirus, or destruction of provirus genomes by gene editing. Elimination of latently infected cells will require a means of exposing this population, which may involve identification of a natural specific biomarker or therapeutic intervention to force their exposure by reactivation of virus expression. Accordingly, the proposed "Shock and Kill" strategy involves treatment with latency-reversing agents (LRA) to induce HIV provirus expression thus exposing these cells to killing by cellular immunity or apoptosis. Current efforts to enable this strategy are directed at developing improved combinations of LRA to produce broad and robust induction of HIV provirus and enhancing the elimination of cells where replication has been reactivated by targeted immune modulation. Alternative strategies may involve preventing re-emergence virus from latently infected cells by "Lock and Block" intervention, where transcription of provirus is inhibited to prevent virus spread or disruption of the HIV provirus genome by genome editing.
引用
收藏
页码:3583 / 3600
页数:18
相关论文
共 166 条
  • [1] A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs
    Abner, Erik
    Stoszko, Mateusz
    Zeng, Lei
    Chen, Heng-Chang
    Izquierdo-Bouldstridge, Andrea
    Konuma, Tsuyoshi
    Zorita, Eduard
    Fanunza, Elisa
    Zhang, Qiang
    Mahmoudi, Tokameh
    Zhou, Ming-Ming
    Filion, Guillaume J.
    Jordan, Albert
    [J]. JOURNAL OF VIROLOGY, 2018, 92 (10)
  • [2] Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing
    Ahlenstiel, Chantelle
    Mendez, Catalina
    Lim, Steven T. H.
    Marks, Katherine
    Turville, Stuart
    Cooper, David A.
    Kelleher, Anthony D.
    Suzuki, Kazuo
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2015, 4 : e261
  • [3] Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection
    Allen, Alexander G.
    Chung, Cheng-Han
    Atkins, Andrew
    Dampier, Will
    Khalili, Kamel
    Nonnemacher, Michael R.
    Wigdahl, Brian
    [J]. FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [4] [Anonymous], 2018, AUD PODC FACT SHEET
  • [5] [Anonymous], 2013, UNAIDS, P1
  • [6] A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy
    Arainga, Mariluz
    Edagwa, Benson
    Mosley, R. Lee
    Poluektova, Larisa Y.
    Gorantla, Santhi
    Gendelman, Howard E.
    [J]. RETROVIROLOGY, 2017, 14
  • [7] Archin NM, 2017, J CLIN INVEST, V127, P3126, DOI [10.1172/JCI92684, 10.1172/jci92684]
  • [8] Advances in antiretroviral therapy
    Arribas, Jose R.
    Eron, Joseph
    [J]. CURRENT OPINION IN HIV AND AIDS, 2013, 8 (04) : 341 - 349
  • [9] Astrocytes sustain long-term productive HIV-1 infection without establishment of reactivable viral latency
    Barat, Corinne
    Proust, Alize
    Deshiere, Alexandre
    Leboeuf, Mathieu
    Drouin, Jean
    Tremblay, Michel J.
    [J]. GLIA, 2018, 66 (07) : 1363 - 1381
  • [10] The role of latency reversal agents in the cure of HIV: A review of current data
    Bashiri, Kiandokht
    Rezaei, Nima
    Nasi, Milena
    Cossarizza, Andrea
    [J]. IMMUNOLOGY LETTERS, 2018, 196 : 135 - 139